Oppenheimer lowered the firm’s price target on Pharming (PHAR) to $41 from $42 and keeps an Outperform rating on the shares. The firm notes the company reported solid Q4 and full-year results. Joenja exceeded Oppenheimer’s expectations for Q4, while Ruconest growth continues to grow despite the launch of oral competitor, which the firm believes is driven by its strong efficacy and differentiated patient population. Oppenheimer is encouraged by continued execution on both the commercial and development front with multiple potential approvals for Joenja in 2026 likely.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
- Pharming Group Posts Strong 2025 Growth, Turns Profitable and Lifts 2026 Outlook
- PHAR Upcoming Earnings Report: What to Expect?
- Pharming Group Sets 2026 Guidance and Showcases Rare Disease Pipeline at Investor Day
- Morning Movers: Disney dips following fourth quarter earnings